Obviously, resolving the question as to whether YAP/TAZ promotes or restricts cancer progression according to the CRC subtype considered is a prerequisite for the potential development of YAP/TAZ targeted therapeutic strategies [45]. This evidence concerns the gene YAP1 and colorectal carcinoma.